Jean-Luc M. Lemercier - 08 Apr 2024 Form 4 Insider Report for Edwards Lifesciences Corp (EW)

Signature
Linda J. Park, Attorney-in-Fact
Issuer symbol
EW
Transactions as of
08 Apr 2024
Net transactions value
-$800,272
Form type
4
Filing time
08 Apr 2024, 17:10:58 UTC
Previous filing
11 Mar 2024
Next filing
01 May 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EW Common Stock Options Exercise $529,200 +14,400 +8.3% $36.75* 188,249 08 Apr 2024 Direct F1
transaction EW Common Stock Sale $9,914 -107 -0.06% $92.65 188,142 08 Apr 2024 Direct F1
transaction EW Common Stock Sale $1,319,558 -14,293 -7.6% $92.32 173,849 08 Apr 2024 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EW Employee Stock Option (Right to Acquire) Options Exercise $0 -14,400 -50% $0.000000 14,400 08 Apr 2024 Common Stock 14,400 $36.75 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 31, 2023.
F2 This transaction was executed in multiple trades at prices ranging from $91.65 to $92.61. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

Remarks:

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. This Form 4 includes quarterly acquisition of shares under the Issuer's Employee Stock Purchase Plan.